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1. Introduction
  Dengue (DEN) virus, a member of the genus Flavivirus 
(family Flaviviridae), is one of the most rapidly spreading 
mosquito-borne human pathogens in the tropics (Figure 
1). DEN viruses are classified into four serotypes (DEN-1, 
DEN-2, DEN-3 and DEN-4), causing a spectrum of 
illnesses ranging from a flu-like disease dengue fever (DF) 
to dengue hemorrhagic fever (DHF), a fulminating illness 
which can progress to dengue shock syndrome (DSS) and 
death[1]. Today DF and DHF/DSS are considered the most 
important arthropod-borne viral diseases in terms of 
morbidity and mortality[2]. The incidence of dengue has 
grown dramatically around the world in recent decades. 
Over 2.5 billion people-over 40% of the world’s population 
are now at risk from dengue. WHO currently estimates there 
may be 50-100 million dengue infections worldwide every 
year. Before 1970, only nine countries had experienced 
severe dengue epidemics. The disease is now endemic 
in more than 100 countries in Africa, the Americas, the 
Eastern Mediterranean, South-east Asia and the Western 
Pacific. South-east Asia and the Western Pacific regions are 
the most seriously affected. Since 2003, dengue cases have 
risen dramatically in Singapore. In 2004, there was a record 
9 459 cases notified with eight deaths, with the highest 
incidence of disease in young adults aged 15-24 years. 
More than three quarters of all dengue cases in Singapore 
were hospitalized[3].
  The African and Eastern Mediterranean regions have also 
recorded more outbreaks of the disease in the last ten years. 
In a recent publication, 22 countries in Africa have reported 
sporadic cases or outbreaks of dengue from 1960-2010[4]. In 
2010, indigenous transmission of dengue was also reported 
in two countries of Europe. Urbanization, rapid movement 
of people and goods, favorable climatic conditions and lack 
of trained staff have all contributed to the global increase of 
dengue. The “official” number of dengue cases in India is 
30 000 the actual number, according to the New York Times, 
Dengue is a common pathogenic disease often proving fatal, more commonly affecting the tropics. 
Aedes mosquito is the vector for this disease, and outbreaks of dengue often cause mass damage 
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Development of a successful vaccine and immunization technique largely remains a challenge and 
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is more than 1 000 times that. But the actual dengue cases in 
India are more than 37 million, according to experts[5].
Figure 1. Mosquito A. aegypti.
1.1. Structure
  Dengue viruses are spherical, lipid-enveloped that contain 
a positive strand RNA genome of approximately 10 200 
nucleotides coding for three structural proteins (capsid, 
membrane and envelope) and seven nonstructural proteins 
(NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5) (Figures 2 and 
3). The envelope protein (E) plays a key role in several 
important processes including receptor binding, blood 
cell hemagglutination, induction of a protective immune 
response, membrane fusion and virion assembly[6]. This 
is a glycoprotein of approximately 55 kDa, with 3 distinct 
domains. Using X-ray crystallography, these domains 
have been characterized for DENV-2 and DENV-3. 
Domain I is located in the center, and domain 栻 contains 
an internal fusion loop which is involved in membrane 
fusion and dimerization of the E protein. Domain 栿 is an 
immunoglobulin-like domain thought to be involved in cell 
receptor binding. Domain 栻 is important, as it contains 
mostly flavivirus group and sub-group crossreactive epitopes. 
The M-protein, which is important in the formation and 
maturation of the viral particle, consists of seven antiparallel 
毬-strands stabilized by three disulphide bonds[7].
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Figure 2. Structure of dengue virus.
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Figure 3. Dengue virus genome.
1.2. Transmission
  All four serotypes of dengue virus have a similar natural 
history, including humans as the primary vertebrate host 
and Aedes mosquitoes of the subgenus Stegomyia [especially 
Aedes aegypti (A. aegypti), Aedes albopictus (A. albopictus) 
and Aedes polynesiensis] as the primary mosquito vectors[8]. 
In Africa, and the Indian subcontinent, dengue viruses also 
exist in enzootic and epizootic forest cycles with nonhuman 
primates as the vertebrate host[9,10]. Other vertebrate species 
are generally not susceptible to dengue viruses, with the 
exception of neonatal mice, challenged intracerebrally. 
After ingestion of a blood meal containing virus, there is 
infection of the epithelial cells lining the midgut. The virus 
then escapes from the midgut epithelium into the haemocele 
and infects the salivary gland. Finally, virus is secreted in 
the saliva, causing infection during probing. The genital 
tract is also infected and virus may enter the fully developed 
egg at the time of oviposition[11]. For transmission to occur, 
the female A. aegypti must bite an infected human during 
the viraemic phase of the illness which generally lasts 4 
to 5 days but may last up to 12 days[12]. A. aegypti may be 
infected with 2 different viruses without affecting the yield of 
either virus[13]. The extrinsic incubation period refers to the 
time required from itself becomes infective. This period is 
about 8 to 12 days[14]. The feeding behaviour of the mosquito 
is characterized by easily interrupted feeding and repeated 
probing of one or several hosts[15].
  Whilst the A. aegypti has a generally low susceptibility 
to oral infection with dengue virus, it remains the most 
important vector because of its highly domesticated 
habits[16].
  The persistence of dengue virus therefore depends on 
the development of high viral titres in hosts to ensure 
transmission in mosquitoes. This vector/virus relationship 
may be a major factor in selecting and propagating 
pathogenic strains of dengue in the urban setting[17].
 
1.3. Signs and symptoms
   In endemic areas, most patients with DF are either 
asymptomatic or present with mild febrile illness[18]. 
The illness ranges from asymptomatic infection, through 
undifferentiated fever and benign DF to severe haemorrhagic 
fever with or without shock syndrome (Figure 4)[19]. 
Others have more severe illness (5%), and in a small 
proportion it is life-threatening[20]. The incubation period 
ranges from 3-14 days, but most often it is 4-7 days[21]. 
Therefore, travellers returning from endemic areas are 
unlikely to have dengue if fever or other symptoms start 
more than 14 days after arriving home[22]. Children often 
experience symptoms similar to those of the common cold 
and gastroenteritis (vomiting and diarrhoea)[23] and generally 
have less severe symptoms than adults, but are more 
susceptible to the severe complications.
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Figure 4. Schematic depiction of the symptoms of dengue fever.
1.4. Clinical course
  The characteristic symptoms of dengue are sudden-onset 
fever, headache (typically located behind the eyes), muscle 
and joint pains and rashes. The alternative name for dengue, 
“break-bone fever”, comes from the associated muscle 
and joint pains[24]. The course of infection is divided into 
three phases: febrile, critical and recovery. The febrile 
phase involves high fever, often over 40 曟 (104 
o
F), and is 
associated with generalized pain and headache; this usually 
lasts for two to seven days[25]. At this stage, rashes occur 
in 50-80% of those with symptoms. It occurs in the first 
or second day of symptoms as flushed skin, or later in the 
course of illness (days 4-7), as measles-like rashes[11]. Some 
petechiae (small red spots that do not disappear when the 
skin is pressed, which are caused by broken capillaries) 
can appear at this point as well as mild bleeding from the 
mucous membranes of the mouth and nose. The fever itself 
is classically biphasic in nature, breaking and then returning 
for one or two days, although there is wide variation in how 
often this pattern actually happens[12,13]. 
  In some people, the disease proceeds to a critical phase, 
which follows the resolution of the high fever and typically 
lasts for one to two days. During this phase, there may be 
significant fluid accumulation in the chest and abdominal 
cavity due to increased capillary permeability and leakage. 
This leads to depletion of fluid from the circulation and 
decreased blood supply to vital organs. During this phase, 
organ dysfunction and severe bleeding, typically from 
the gastrointestinal tract, may occur. Shock (DSS) and 
hemorrhage (DHF) occur in less than 5% of all cases of 
dengue, however those who have previously been infected 
with other serotypes of dengue virus (“secondary infection”) 
are at an increased risk[26]. 
  The recovery phase occurs next, with resorption of the 
leaked fluid into the bloodstream. This usually lasts for 
two to three days. The improvement is often striking, but 
there may be severe itching and a slow heart rate. Another 
rash may occur with either a maculopapular or a vasculitic 
appearance, which is followed by peeling of the skin. During 
this stage, a fluid overload state may occur; if it affects the 
brain, it may cause a reduced level of consciousness or 
seizures. A feeling of fatigue may last for weeks afterwards[8]. 
2. Dengue diagnosis
  Three factors have been fundamental in dengue diagnosis:
2.1. Development of ELISAs for dengue-specific IgM 
detection
  The diagnostic test employed most commonly is IgG and 
IgM antibodies assay by ELISA. This test is based on an 
increase in the IgG titre by a factor of four, is difficult in 
routine clinical care because a second blood sample is 
required at the convalescent stage[27]. Primary infections 
are characterized by an increase in dengue-specific IgM 
antibodies four to five days after the onset of fever and 
by an increase in IgG antibodies. Only after seven to ten 
days, IgM antibodies are detectable for three to six months, 
whereas IgG antibodies remain detectable for life. In 
secondary infections, the level of IgM antibodies is lower 
than in primary infections and the antibodies are sometimes 
absent, whereas levels of IgG antibodies rise rapidly in 
secondary infections, even during the acute phase. Thus, 
the presence of high titers of IgG early in the course of the 
disease is a criterion for secondary infection. The sensitivity 
of IgM ELISA ranges from 90%-97% as compared with the 
gold standard haemagglutination inhibition test. Some 
false positive reactions can be observed in less than 2% 
of cases and a low or negative IgM reaction in secondary 
infections[28]. A number of commercial kits are available in 
the market used for detection of anti-dengue antibodies[29-
36]. 
2.2. Mosquito cell lines and monoclonal antibody 
development for viral isolation and identification
  This method depends on the availability of host-cell 
cultures or mice that serve as an indicator of virus infection, 
ie. cytopathic effects in cell culture, sign of illness or 
death in mice. This is the most common method for virus 
isolation[37].
  Several continuous mosquito cell lines have been known to 
be highly susceptible to dengue virus infection. The C6/36 
clone of A. albopictus cells was chosen for virus isolation 
because it high sensitivity to dengue virus infection and 
ease of handling[38,39].
  Mosquito cell cultures are a recent addition to dengue virus 
isolation methodologies. Three cell lines of comparable 
sensitivity are most frequently used. The C6/36 clone of 
A. albopictus cells is less sensitive than the mosquito 
inoculation method. Use of these cell lines has provided a 
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rapid, sensitive and economical method for dengue virus 
isolation. The sensitivity mosquito cell lines may vary with 
the strain of the virus. Even though cell cultures are less 
sensitive than the mosquito inoculation, large number of 
samples can be processed in a relatively short time[40]. 
Mammalian cell cultures have many of the same advantages 
as baby mice for isolation of dengue viruses, such as being 
expensive, slow and intensive[41].
2.3. Reverse transcriptase PCR
  In recent years, reverse transcriptase-polymerase chain 
reaction (RT-PCR), has been developed for a number of 
RNA viruses, including dengue viruses. Unlike most other 
techniques which require screening of pools of mosquitoes 
to detect viruses, RT-PCR carries out the job with solitary 
specimen. The technique allows for the multifold biological 
amplification of viral nucleic acid and has been used to 
rapidly diagnose viral diseases[42-45]. The primary advantage 
of this molecular tool lies in the speed at which specimens 
can be screened for the presence of dengue viruses and also 
by its highly sensitive and specific detection. It is able to 
monitor the infection rate in mosquitoes, both adults and 
larvae, with a high degree of precision[46]. RT-PCR can also 
detect small quantities of virus-3. This method has also 
been employed for detecting and typing dengue virus RNA 
in the field caught Aedes mosquitoes, besides determining 
the infection rate in local Aedes mosquitoes[47].
  These three methods cover the serological, virological, and 
molecular diagnosis of dengue[48].
3. Tissues/Organs affected by dengue
  Several body organs are affected by dengue in many ways.
3.1. Liver 
  The spectrum of hepatic involvement in dengue varies from 
jaundice to elevation in liver enzymes[49]. Hepatomegaly 
and increased serum liver enzymes are the two most clinical 
evidence of the involvement of liver in dengue infection. 
It has been reported that among the two, hepatomegaly 
is more frequent in patients with DHF than in those with 
DF. Several studies document raised serum transaminase 
levels in dengue infection (higher in DHF/DSS than in DF), 
however these tend to return to normal in 14-21 days after 
infection[50]. The enzymes, aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT), are believed to be highly 
sensitive indicator of liver damage. The studies conducted 
by Kuo and colleagues on nearly 240 dengue patients from 
the 1987-1988 outbreak in Taiwan showed elevated levels 
of AST and ALT in 93.3% and 82.2% of cases respectively[51]. 
Presence of fever, jaundice and hepatomegaly in endemic 
areas should arouse the suspicion of dengue hepatitis.
3.2. Heart 
  Dengue continues to cause significant global morbidity and 
mortality. Severe disease is characterized by cardiovascular 
compromise from capillary leakage. Cardiac involvement 
in dengue has also been reported but has not been 
adequately studied. Studies have reported patients with 
severe dengue had septal and right ventricular wall being 
predominantly affected leading to systolic and diastolic 
cardiac impairement[52]. During episodes of DHF, cardiac 
rhythm disorders such as atrioventricular blocks, atrial 
fibrillation, sinus node dysfunction and ectopic ventricular 
beats have been reported. Cases of complicated dengue 
viral infection with acute myocarditis involving young male 
adults have been reported. Two cases were studied of which 
one was fatal. The first case presented with typical signs 
of myocardial disease: chest pain and diaphoresis with 
myocardial depression. The second case deteriorated rapidly 
and demised within the first day of admission[53]. However, 
the incidence of cardiac complications in patients with 
dengue illness varies greatly[54,55]. 
  Further studies carried out by Wali et al showed that 70% 
of 17 patients with DHF/DSS who underwent myocardial 
scintigraphic study suffered diffuse left ventricular hypo 
kinesis with a mean ejection fraction of 40%[55]. Whereas 
Kabra et al reported that 16.7% of 54 children with dengue 
illness had a decreased left ventricular ejection fraction of 
<50%[56]. 
  These studies suggest that cardiac complications in dengue 
illness are not uncommon, but have been under-diagnosed 
as cases with cardiac complications are clinically mild 
and self-limited. Although severe cardiac impairment is 
not commonly reported in dengue infection, it can be life 
threatening.
3.3. Kidney
  Dengue shock syndrome is the most severe form of dengue 
that can be fatal. Nonresponders to standard therapy 
need intensive care. A report on the clinical features, 
complications, and outcomes of DSS not responding to 
standard therapies and needing supportive care in a tertiary 
referral intensive care unit of a developing country indicated 
that nearly one-third died within 3 days of admission to ICU. 
Peritoneal dialysis increased the risk to 100%[57]. Acute renal 
failure is rare in dengue fever and it mainly presents as 
shock induced acute tubular necrosis. It has been observed 
as a complication of dengue fever in French Guiana and was 
found to occur in 0.3% of cases in a series of 6 154 patients 
with DHF. Acute renal failure and multiple organ failure 
can also be a manifestation of rhabdomyolysis. The role of 
immune complex in development of renal failure in dengue 
infection is still unclear. Wiwanitkit discovered that the 
diameter of dengue virus-immunoglobulin complex is much 
smaller than the diameter of glomerulus. Thus, he postulated 
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that immune complex can be entrapped only if a previous 
glomerular lesion causes narrowing of the glomerulus’s 
diameter, and concluded that the immune complex does 
not play a significant role in pathogenesis of renal failure 
in dengue infection. Reports of renal failure because of 
haemolytic uraemic syndrome are rare[58]. 
3.4. Eye
  Studies on ocular complication in dengue fever have 
been reported in literature. These ocular manifestations 
may be a result of inflammatory changes in vascular 
endothelium resulting in vascular leakage, haemorrhage 
and ischaemia. Ocular manifestations reported in DHF are 
subconjunctival hemorrhage, intraretinal haemorrhage, 
macular haemorrhage, vitreous hemorrhage, Roth spots, 
cotton wool spots, retinal oedema, disc oedema or choroidal 
effusion. A characteristic maculopathy has only rarely been 
reported and may be due to actual infection of macular 
tissue. This maculopathy may manifest itself reduced 
visual acuity, abnormal visual fields or electrophysiological 
studies. Good recovery is the norm but exceptions have 
been seen in patients with macular hemorrhages[59]. The 
spectrum of ophthalmologic manifestations would lead one 
to conclude that several pathophysiologic processes are 
involved. The first and most obvious pathogenesis would 
be the thrombocytopenic state, with its resultant bleeding 
tendency, which gives rise to increased incidence of 
hemorrhage. These hemorrhages manifest as retinal blot 
hemorrhages in the macula and retinal periphery. Most 
patients with dengue-related ophthalmic complications 
recover spontaneously without any treatment.  Despite this, 
isolated reports of cases of dengue ophthalmic complications 
with poor visual acuity refractory to treatment have been 
reported[60]. 
3.5. Blood
  In severe condition of dengue, the fibrinolytic system has 
also been found to get greatly disturbed. Such fibrinolytic 
abnormalities suggest a stressed haemostatic system that 
may ultimately result in overt disseminated intravascular 
coagulation[61].
  Thrombocytopenia is common in DF and always found 
in dengue hemorrhagic fever/ dengue shock syndrome[62]. 
However, the pathogenesis of thrombocytopenia is unknown 
and it is believed that dengue- virus-induces bone marrow 
suppression leading to depressed platelet synthesis and 
thrombocytopenia[63].
  Another study reported that dengue-2 virus can bind 
to human platelets in the presence of virus-specific 
antibodies, and proposed that the immune-mediated 
clearance of platelets was involved in the pathogenesis 
of thrombocytopenia in DHF/DS[64]. The titre of IgM anti-
platelet antibodies is higher in DHF/DSS than in DF patients. 
The presence of these auto antibodies not only induces 
platelet lysis via complement activation, but also inhibits 
ADP-induced platelet aggregation[65]. The production of 
anti-platelet autoantibodies whose affinities are enhanced in 
secondary infection not only explains the immune-mediated 
destruction of platelets, but also raises an important issue of 
the long-term safety of a dengue vaccine. 
3.6. Brain 
  Encephalopathy in DHF is an atypical manifestation and 
may occur because of various reasons such as intracranial 
haemorrhage, cerebral oedema, hyponatremia, cerebral 
anoxia, fulminant hepatic failure with portosystemic 
encephalopathy, renal failure or release of toxic products. 
The signs and symptoms of neurological involvement 
appear in various forms, including depressed sensitivity, 
convulsions, neck rigidity, pyramidal signs, headache, 
papilloedema, myoclonus and behavioural disorders. Post-
infectious sequelae are mainly amnesia, dementia, manic 
psychosis, Reye’s syndrome and meningo encephalitis. 
Pathophysiology may include the following factors: 
direct tissue lesion caused by the virus because of its 
neurotropicity, capillary haemorrhage, disseminated 
intravascular coagulation and metabolic disorders[66]. 
  In a study, it was reported that dengue virus was observed 
in the cerebrospinal fluid (CSF) in five of six patients 
presenting with encephalitis, indicating that the virus 
may cross the blood-brain barrier and directly invade 
the brain. In another study, samples of 150 individuals 
suspect of an infection disease and with fatal outcomes 
were investigated for evidence of the presence of DENV. 
The sampling was made up of 150 CSF, 120 tissue samples, 
and 109 blood specimens. Out of 150 studied patients, 84 
were dengue positive. Evidence of the presence of DENV 
was found in 41 CSF, showing the following neurologic 
diagnosis: 46.3% encephalitis, 34.1% meningoencephalitis, 
and 19.5% meningitis, giving a frequency of 48.8% of the 84 
dengue-positive cases. The major clinical manifestations 
observed on these individuals were fever, headache, mental 
irritability, breathless, vomiting, muscle pain, tiredness, 
abdominal pain, somnolence, restlessness, dizziness, cough, 
seizure, coma, and neck stiffness[67,68]. 
3.7. Pancreas
  Acute pancreatitis is a rare complication of dengue fever. 
Pancreas may be affected due to direct viral invasion or 
hypotension in dengue hemorrhagic fever.  Case studies of 
dengue lead to an emphasis on the possibility of dengue 
related pancreatitis in patients with abdominal pain 
and fever. This will help the patient to receive adequate 
monitoring and supportive care directed at the management 
of dengue along with the management of acute pancreatitis. 
The exact pathogenesis in the development of acute 
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abdomen from infection with dengue virus is unknown. 
However, it might be due to virus invasion of the gallbladder 
wall, appendicular wall or pancreas, which causes 
oedematous change.  Recently a case study was reported 
wherein acute pancreatitis as the complication of DHF 
was studied. Although rare, this complication can cause 
more severe fatal condition, and difficulties in treatment. 
Acute pancreatitis is an uncommon but life-threatening 
complication of dengue fever[69]. Early diagnosis and quick 
management of dengue related complications is necessary to 
improve the patient’s condition and survival[70].
3.8. Effect on Endothelial cells
  The endothelium is the primary fluid barrier of the 
vasculature and ultimately the effects of dengue virus 
infection that bring about capillary leakage impact 
endothelial cell barrier functions. Infection of endothelium 
by dengue virus alters capillary permeability, permits virus 
replication and induces responses that recruit immune 
cells to the endothelium[71]. In a postmortem study, Jessie 
et al reported dengue virus antigen in sinusoidal ECs in 
the liver as well as macrophages, lymphoid cells in the 
spleen, the vascular endothelium of the lung, monocytes 
within the blood, and kidney tubules[72].  Salgado et 
al. also demonstrated the presence of viral antigen in 
endothelial cells within the heart and small myocardial 
vessels of a patient post-mortem[73]. Leakage of the vascular 
endothelium is a central component of dengue virus 
disease and studies discussed here suggest that the dengue 
infected endothelium may contribute to pathogenic immune 
responses and immune targeting of the endothelium.
3.9. Pregnant patients
  Dengue in pregnancy must be carefully differentiated from 
preeclampsia. An overlap of signs and symptoms, including 
thrombocytopenia, capillary leak, impaired liver function, 
ascites and decreased urine output may make this clinically 
challenging. Pregnant women with dengue fever respond 
well to the usual therapy of fluids, rest and antipyretics. 
An awareness of the clinical and laboratory manifestations 
of dengue in pregnancy should allow its early recognition 
and the institution of appropriate treatment. If the mother 
acquires infection in the peripartum period, newborns 
should be evaluated for dengue with serial platelet counts 
and serological studies[74,75]. Dengue fever in pregnancy 
most often is treated conservatively. Complications like pre-
eclampsia, pre-term labour, increased risk of caesarean 
section and fetal transmission have been noted.  Platelet 
count may fall rapidly but no active intervention required 
unless patient is in labour or has bleeding disorder[76].
4. Treatment against dengue 
  Treatment of dengue may involve following four parameters 
which may or may not be successful.
4.1. Vaccination
  The development of a dengue vaccine has unique 
challenges. The four dengue serotypes circulate globally 
and infection with one dengue serotype confers life-long 
protection against re-infection with the same serotype, but 
only short-term protection against the other 3 serotypes. 
Moreover, dengue is unique in that sequential infections 
with different serotypes increase the risk of developing 
severe and potentially lethal disease[77]. There is limited 
understanding of how the virus interacts with the immune 
system and how certain types of pre-existing immunity can 
exacerbate disease. Therefore, a safe and effective dengue 
vaccine must be tetravalent and induce strong and long-
lived protection against all 4 serotypes simultaneously in 
order to avoid the risk of sensitizing the vaccine recipient 
to severe disease[78]. There are a number of dengue vaccine 
candidates in different stages of development. The more 
advanced consist of tetravalent mixtures of live attenuated 
viruses representing each serotype. Different attenuation 
mechanisms have been used to develop three of the leading 
candidates:
 a) Chimerization with yellow fever 17D vaccine strain, 
developed by Sanofi Pasteur.
 b) Combinations of defined mutations/deletions and 
chimeras, developed by NIH.               
 c) Chimerization with dengue 2 PDK53 virus, attenuated by 
cell culture passage, developed by Inviragen.
But several disadvantages are associated with all live 
attenuated vaccine:
1)Single inoculation is not sufficient to induce protection to 
all 4 serotypes, probably due to viral interference among the 
live components of the vaccine.
2)Booster doses are not effective when administered less 
than 6 months apart.
  Therefore, live attenuated vaccines require three 
immunizations over an extended dosing schedule of 12 
months to elicit balanced neutralizing antibody responses to 
all 4 serotypes. As a result, there is a risk that an incomplete 
response induced by the initial immunizations will enhance 
disease if infection occurs during the window between the 
first and the last immunization.
4.2. Medication /Treatment
  Dengue fever is usually a self-limited illness. There is no 
specific antiviral treatment currently available for dengue 
fever. Supportive care with analgesics, fluid replacement 
and bed rest is usually sufficient[79].
  No medication has been found to be useful in treatment 
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dengue and its association disorder or complication. 
However, Acetaminophen may be used to treat fever 
and relieve other symptoms. Aspirin, nonsteroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids should be 
avoided. Management of severe dengue requires careful 
attention to fluid management and proactive treatment 
of hemorrhage. Single-dose methylprednisolone showed 
no mortality benefit in the treatment of dengue shock 
syndrome in a prospective, randomized, double-blind, 
placebo-controlled trial[80]. 
  The Novartis Institute for Tropical Diseases (NITD) in 
Singapore is carrying out research to find inhibitors of 
dengue viral target proteins to reduce the viral load during 
active infection[81].
  Some measures can be taken as a supportive care in 
dengue fever. They can be classified in to two categories:
4.2.1. For suspected dengue
  1) Patients with moderate dehydration caused by high fever 
and vomiting are recommended oral rehydration therapy.
  2) Should have their platelet count and hematocrit 
measured daily from the third day of illness until 1-2 days 
after defervescence.
  3) Patients with clinical signs of dehydration and a 
rising hematocrit level or falling platelet count should 
have intravascular volume deficits replaced under close 
observation[82].
4.2.2. For severe dengue
  1)Severe dengue requires careful attention to fluid 
management and proactive treatment of hemorrhage. 
Admission to an intensive care unit is indicated for patients 
with dengue shock syndrome.
  2)Patients may need a central intravenous line for volume 
replacement and an arterial line for accurate blood pressure 
monitoring and frequent blood tests[83]. 
  3)Intravascular volume deficits should be corrected with 
isotonic fluids such as Ringer lactate solution.
  4)Boluses of 10-20 mL/kg should be given over 20 minutes 
and may be repeated. 
  5)If this fails to correct the deficit, the hematocrit value 
should be determined. If it is rising, limited clinical 
information suggests that a plasma expander may be 
administered. Starch, dextran 40, or albumin 5% at a dose 
of 10-20 mL/kg may be used. One study has suggested 
that starch may be preferable because of hypersensitivity 
reactions to dextran[84]. 
4.3. Natural treatment options for dengue fever
  Natural drugs possess activity against A. aegypti by their 
antiviral mechanism, larvicidal and mosquitocidal action 
and mosquito repellants property. Some of the important 
natural cures are enumerated below.
1) Eupatorium perfoliatum (Boneset): Bonoset is a commonly 
available plant which plays an important role in management 
of dengue fever. It is best consumed in the form of a tea[85].
2) Boesenbergia rotunda (Temu kunci): A paste made with the 
roots is often used for treatment. The use of the herb reduces 
muscular pain and nausea which causes great distress in 
people who suffer from this condition[86].
3) Kaempferia parviflora: Leaves and stem are used as 
herbal remedy against virus. Studies have shown that 
DEN 2 particles are directly inactivated by some bioactive 
compound in Kaempferia parviflora[87].
4) Carica papaya: Juice of the leaves is utilized for 
increasing the platelet count[88].
5) Solanum villosum: Berry extract is reported to possess 
larvicidal activity against Stegomyia aegepti[89].
6) Combretum collinum: Extract of shoot bark possess 
larvicidal against A. aegypti[90].
7) Azadirecta indica and Pongamia glabra: Herbal 
formulation named PON-NEEM imparts larvicidal, ovicidal, 
oviposition deterrant activity against A. aegypti and A. 
albopictus[91].
8) Nyctanthes arbortistis, Catharanthus roseus, Eupatorium 
odoratum: Leaf extract exert larvicidal activity against A. 
aegypti[92].
9) Citrus limetta: Extract from peels exert larvicidal activity 
against A. aegypti[93].
10) Acalypha alnifolia: Leaf extract exert larvicidal activity 
against A. aegypti, Aedes stephensi (A. stephensi)[94].
11) Delonix elata: Leaf and seed extracts are reported to 
exert larvicidal and ovicidal activities against A. aegypti and 
A. stephensi[95].
4.4. General prevention
  The only way to prevent dengue virus acquisition is to 
avoid being bitten by a vector mosquito. Although this can 
be accomplished by avoiding travel to areas where dengue 
is endemic, that is not an ideal strategy because it would 
require a person to avoid most tropical and subtropical 
regions of the world, many of which are popular travel and 
work destinations[96]. Other measures are as follows: 
a) Apply N,N-diethyl-3-methylbenzamide-containing 
mosquito repellant;
b) Wear protective clothing, preferably impregnated with 
permethrin insecticide;
c) Remain in well-screened or air-conditioned places;
d) The use of mosquito netting is of limited benefit, as Aedes 
are day-biting mosquitoes;
e) Eliminate the mosquito vector using indoor sprays[97,98].
5. Conclusion
  The authors aimed at presenting an overview on dengue, 
a common pathogenic disease. An exhaustive, cumulative 
and in-depth literature review has been used to present 
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the details of the etiology, transmission and treatment 
models with special emphasis on drugs of natural origin. 
The pathophysiological changes on several major body 
organs have been dealt in great detail. The myths regarding 
the disease need to be avoided and the safe bet as always 
remains: prevention is better than cure! 
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